FDA Accepts Roflumilast Foam NDA for the Treatment of Seborrheic Dermatitis

Press/Media

Period	1 Apr 2023

Media coverage

Title	FDA Accepts Roflumilast Foam NDA for the Treatment of Seborrheic Dermatitis
Media name/outlet	Dermatology Times
Country/Territory	United States
Date	1/04/23
URL	metabase.moreover.com/noarticleurl?type=psh&lni=6821-FYX1-F0CR-J23X-00000-00
Persons	Peter Lio